Exhalix, LLC

Key People

• Reza Shekarriz, Ph.D. - Chief Executive Officer & Founder

Assessment

Team

Aspect: First-time 10+ yrs
Summary: Led by founder with over a decade of experience.

The CEO and founder, Reza Shekarriz, Ph.D., brings over ten years of experience to Exhalix, indicating a solid foundation for the company's leadership. ([pitchbook.com](https://pitchbook.com/profiles/company/181754-83?utm_source=openai))

Clinical Need

Aspect: Very Strong
Summary: Addresses significant unmet needs in vascular health.

Exhalix focuses on non-invasive diagnostics and minimally invasive therapeutic technologies for detecting and treating lower extremity vascular health issues, such as peripheral artery disease (PAD), chronic wounds, and chronic limb-threatening ischemia (CLTI). These conditions affect millions and represent a substantial unmet clinical need. ([exhalix-llc.com](https://exhalix-llc.com/?utm_source=openai))

Competition

Aspect: Somewhat crowded
Summary: Operates in a competitive market with several players.

The market for non-invasive diagnostic devices and therapeutic technologies in vascular health is competitive, with several established companies offering similar solutions. ([flairinsights.com](https://flairinsights.com/report-description/breath-sampler-market-size-and-forecast?utm_source=openai))

Technical Challenge

Aspect: Moderate
Summary: Development involves moderate technical complexity.

Developing non-invasive diagnostic devices and therapeutic systems like TAGS and HEALS involves integrating advanced sensor technologies and ensuring accurate measurement of biomarkers, which presents moderate technical challenges. ([exhalix-llc.com](https://exhalix-llc.com/?utm_source=openai))

Patent

Aspect: Strong
Summary: Holds strong patent positions for key technologies.

Exhalix has secured patents for its technologies, including a transdermal sampling strip for analyzing transdermally emitted gases, which strengthens its intellectual property position. ([patentsgazette.uspto.gov](https://patentsgazette.uspto.gov/week32/OG/html/1525-1/US12053281-20240806.html?utm_source=openai))

Financing

Aspect: SBIR/SEED
Summary: Secured funding through government grants.

Exhalix has received significant funding from the National Science Foundation and the U.S. Department of Health and Human Services, totaling over $3 million, supporting its research and development efforts. ([taggs.hhs.gov](https://taggs.hhs.gov/Detail/RecipDetail?arg_EntityId=s%2F1imleVje5TFXaEbjb1Kw%3D%3D&utm_source=openai))

Regulatory

Aspect: Running FIH
Summary: Conducting first-in-human trials for products.

Exhalix is advancing its products through the regulatory process, with ongoing first-in-human trials for its diagnostic and therapeutic devices, indicating positive momentum towards market approval. ([exhalix-llc.com](https://exhalix-llc.com/?utm_source=openai))

Opportunity Rollup

Odds of Success

4

Peak Market Share

5.7

Segment CAGR

4.4%

Market Segment

Peripheral Vascular Devices

Market Sub Segment

Non-Invasive Diagnostics

Key Takeaway

Exhalix, LLC is well-positioned in the non-invasive vascular diagnostics market, leveraging strong leadership, significant funding, and a robust IP portfolio to address critical clinical needs, despite facing a competitive landscape and technical challenges.